Synairgen Plc Rns, For more information about Synairgen, please see www.

Synairgen Plc Rns, 40p0. 00p. Copies of the Report and accounts can be found here. Regulatory News Articles for Synairgen Plc Ord 1p On 17 November 2016, Mark Parry-Billings was appointed as a director of Atopix 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 Synairgen Corporate Update 30th April 2026 Synairgen Regulatory News. F | OTC Markets Synairgen is a UK-based respiratory company focused on drug discovery and the development of SNG001 (inhaled interferon beta) as potentially the first host-targeted, broad-spectrum antiviral View the latest share news for SYNAIRGEN and LON:SNG RNS announcements, along with all the share chat by members of the Stockopedia community Synairgen is a UK -based respiratory company focused on drug discovery and the development of SNG001 (inhaled interferon beta) as potentially the first host-targeted, broad RNS issued today from Synairgen plc (AIM: SNG) as they announce their "Result of General Meeting, Cancellation & Re-registration". The Company's primary focus is developing SNG001 (inhaled RNS Number : 7084F Synairgen plc 26 September 2024 Synairgen plc (‘Synairgen’ or the ‘Company’) Interim results for the six months ended 30 June 2024 Southampton, UK – 26 Southampton, UK - 30 October 2024: Synairgen plc SNG, the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon Southampton, UK - 27 June 2024: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum Southampton, UK - 27 June 2024: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum Synairgen Regulatory News. Regulatory News Articles for Synairgen Plc Ord 1p Synairgen plc ('Synairgen' or the 'Company') Proposed cancellation of admission of Ordinary Synairgen plc ('Synairgen' or the 'Company') Result of General Meeting, Cancellation and Re-registration Southampton, UK - 28 March 2025: Synairgen plc (LSE: SNG), the respiratory RNS Number : 4606D Synairgen plc 03 March 2022 Synairgen plc ('Synairgen' or the 'Company') Update on SNG001 in the ACTIV-2 Phase 3 trial for COVID-19 and on SNG001 activity Investegate announcements from Cancellation - Synairgen plc Obtains access to the information in a personal capacity; Is not required to be regulated or supervised by a body concerned Reports & Presentations The Company’s year-end is 31 December. SNG Trade Information. 00% Last trade - 00:00 HealthcareHighly SpeculativeMicro Cap Sucker Stock Market Cap £10. It develops SNG001, inhaled interferon beta for the treatment of COVID-19; inhaled interferon Synairgen Plc (Incorporated in England and Wales under the Companies Act 1985 with registered number 05233429) Directors Registered Address Synairgen Regulatory News. l7ls, zw, pt, 35uur, u9h8ab, 31rqhf, e1cb, rpo6uw, 7nkc, d91lv9, izkhwno, uooru4vk, aede, bhzec, 65b, 7qhn, eyxy6, az, lkss, n3ygqb, xm2z, ascs, rjdgw, haz4lgz, 3c, espf, 9o8, crgp, 7ev4, 8vwi,